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Abstract
Introduction: Patient registries serve an important role in rare disease research, particularly for the 
recruitment and planning of clinical trials. The Canadian Neuromuscular Disease Registry was estab-
lished with the primary objective of improving the future for neuromuscular (NM) patients through 
the enablement and support of research into potential treatments.
Methods: In this report, we discuss design and utilization of the Canadian Neuromuscular Disease 
Registry with special reference to the paediatric cohort currently enrolled in the registry.
Results: As of July 25, 2017, there are 658 paediatric participants enrolled in the registry, 249 are dys-
trophinopathies (229 are Duchenne muscular dystrophy), 57 are myotonic dystrophy participants, 98 
spinal muscular atrophy participants and 65 are limb girdle muscular dystrophy. A total of 175 patients 
have another NM diagnosis. The registry has facilitated 20 clinical trial inquiries, 5 mail-out survey 
studies and 5 other studies in the paediatric population.
Discussion: The strengths of the registry are discussed. The registry has proven to be an invaluable 
tool to NM disease research and has increased Canada’s visibility as a competitive location for the con-
duct of clinical trials for NM therapies.
Keywords:  Clinical trials; Neuromuscular; Rare disease; Registry; Surveys
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There are over 150 neuromuscular (NM) disorders, as delin-
eated by the World Federation of Neurology (1). The most 
common childhood NM diseases are: Duchenne muscular dys-
trophy (DMD), with an incidence of between 1 in 3500 and 1 in 
5000 newborn males; myotonic dystrophy (DM), with a preva-
lence of between 0.5 and 18.1 in 100,000 worldwide (2,3); and 
spinal muscular atrophy (SMA), which has an incidence of 1 in 
11,000 live births (4).
Patient registries serve as important tools for organizing 
patient clinical and demographic information, as well as acceler-
ating and supporting translational research. Registries are espe-
cially important for rare disease communities in the recruitment 
and facilitation of clinical trials (5,6). Patient registries such as 
the Canadian Neuromuscular Disease Registry (CNDR) pro-
vide a platform whereby the target populations can be quickly 
and easily identified across a national complement of clinics 
facilitating research activities and investigator collaboration.
The CNDR was established in 2011 as a tool that connects 
both adult and paediatric Canadians living with a NM disease 
with national and international research opportunities. Apart 
from planning and recruitment for clinical trials, which has 
been the principal activity, survey, epidemiological and natu-
ral history studies have been conducted using participants and 
patient information obtained from the CNDR (7).
The CNDR is part of a multinational effort to coordinate and 
consolidate NM disease registry data to enable broader high-im-
pact research efforts. In this regard, the Translational Research 
in Europe for the Assessment and Treatment of Neuromuscular 
Disease (TREAT-NMD) Alliance is a global effort configured 
to harmonize translational research in NM disease. One of 
TREAT-NMD’s main goals is the development of a set of stan-
dardized principles and a consistent framework for NM patient 
registries. With this framework in place to foster a collabora-
tive environment, the TREAT-NMD Global registry group has 
been able to publish large studies addressing important issues 
for the NM community (5,8). The CNDR is a participating 
member of the TREAT-NMD Global registry alliance and con-
tributes data on behalf of Canadian patients to this important 
international collaboration.
The CNDR collects detailed medical data on four rare 
paediatric NM diseases collectively known as ‘indexed’ dis-
eases (DMD, DM, SMA and limb girdle muscular dystrophy 
[LGMD]). Data are updated at a minimum interval of once in 
every 12 months. The registry also enrols other childhood-on-
set NM disorders, collecting only contact details, basic demo-
graphics (e.g., age, gender) and a diagnosis. These diseases are 
termed ‘non-indexed diseases’. Depending on resource and 
funding availability to support active recruitment and track-
ing, a non-indexed disease may become an indexed disease. In 
this report, we discuss the design and utilization of the registry 
and describe the paediatric population currently enrolled. The 
objective of this paper is to raise awareness among Canadian 
paediatricians and paediatric subspecialists about the registry 
and highlight the valuable nature of this tool for collaborative 
research in rare childhood disorders.
METHODS
Objectives
The CNDR aims to improve the future for Canadians with NM 
disorders through the enablement and support of research that 
enhances the understanding of epidemiology of NM diseases 
in Canada, attracts international trial opportunities and fosters 
collaboration among Canadian investigators.
Registry design
The CNDR operates as a network of university-affiliated NM 
clinics and local principal investigators. Adult and paediatric 
clinics function as separate sites even if they are in the same city 
or even institution. Although the focus of this paper is on the 
paediatric component of the registry, the organization and pro-
cesses between the adult and paediatric components are identi-
cal. Patient enrollment from clinics is supported and overseen 
centrally by the CNDR National Office at the University of 
Calgary. Each clinic obtains local research ethics board approval 
using a standardized ethics package that is common across all 
centres.
Patient eligibility and consent
All children and adults living in Canada with a NM condition 
are eligible for enrollment into the registry. The majority of 
participants enrolled in the registry are enrolled during routine 
clinic visits by a research coordinator or clinician. In addition, 
patients not attending an affiliated clinic or otherwise with-
out specialist care may self-register by contacting the CNDR 
National Office. Any physician in Canada may also refer their 
patients to the CNDR by directing them to the CNDR National 
Office.
Data collection and management
Clinical data are collected retrospectively by trained research 
personnel accessing clinic charting or by the attending phy-
sician or a trained research coordinator during a clinic visit. 
Identified and de-identified data are directly entered into a 
secure web portal. De-identified medical data quality and com-
pliance audited by CNDR National Office staff.
Access to CNDR data
Access to de-identified aggregated registry data is facilitated 
through a formal application process. There are two types of 
data requests: research proposal requests and statistical data 
requests. Research proposals involve the export of de-identified 
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CNDR data for research use or use of identified data by CNDR 
National Office staff to contact CNDR subjects for research 
study participation on behalf of the study team and/or spon-
sor. Proposals may be submitted by an investigator or sponsor 
and must include approval from a relevant ethics board. These 
studies are then reviewed by the CNDR Advisory Committee.
Statistical data requests involve an application for aggregated 
statistics such as information on the distribution of patients in 
Canada by location or by disease group. These requests do not 
involve the export of records from the CNDR and are of a data 
granularity that does not risk individual identification. These 
requests are typically used to inform study feasibility or to pro-
vide information for government analysis, charitable inquiries 
or pharmaceutical company clinical trial planning. Typically, 
the request is driven by the need to examine aggregate data to 
better understand patient numbers and characteristics across 
Canada. All data inquiries are reviewed by the CNDR Advisory 
Committee. In addition to exporting data and providing statisti-
cal information, the CNDR also facilitates notification through 
mail-outs to eligible study participants and can provide custom 
study data collection or facilitate the collection of anonymized 
study data through survey mail-outs.
RESULTS
The CNDR began paediatric enrollment in June of 2011 
and as of July 25, 2017 totals 658 participants (19% of 
 registry overall).
Ten of the 24 CNDR clinics recruit paediatric participants 
(Table 1). Figure 1 shows the breakdown of all paediatric NM 
diseases. Dystrophinopathies account for the largest proportion 
of participants, followed by SMA, LGMD and DM, together 
making up 71.3% of the entire paediatric population. Table 2 
summarizes the genetic characteristics of these index disease 
participants, and Table 3 summarizes other clinical information 
such as ventilation status.
Since its launch, the CNDR has approved 30 studies that 
involve the paediatric population: 20 were clinical trial inqui-
ries, 5 were mail-out surveys and 5 were other studies. The 
five mail-out survey studies included two that examined the 
quality of life in boys with DMD (9), parent-reported dis-
ease burden of congenital and childhood-onset DM (10); an 
access to technology survey for individuals with DM, and a 
respiratory needs survey in boys with DMD and SMA. Five 
other studies included a study of congenital DM; a study of 
a respiratory intervention in children; an inquiry regarding 
ventilation support use in paediatric patients with type I DM; 
an inquiry regarding steroid use, growth and walking ability 
in DMD patients; and a study on genetics of dystrophinopa-
thies and disease severity.
DISCUSSION
The CNDR has grown to be a valuable national tool in the facilita-
tion of research in children with NM disorders. From an interna-
tional perspective, the CNDR is one of 49 registries that enroll DMD 
Table 1. Current and former paediatric neuromuscular clinics participating in the Canadian Neuromuscular Disease Registry
City Clinical site Academic institution Site principal investigators
Current
 Vancouver, BC BC Children’s Hospital University of British Columbia Dr. Kathryn Selby
 Calgary, AB Alberta Children’s Hospital University of Calgary Dr. Jean Mah
 Toronto, ON Holland Bloorview Kids Rehabilitation 
Hospital
University of Toronto Dr. Laura McAdam and  
Dr. Doug Biggar
 London, ON Thames Valley Children’s Centre Western University Dr. Craig Campbell
 Ottawa, ON Children’s Hospital of Eastern Ontario University of Ottawa Dr. Anna McCormick and 
Dr. Hugh McMillan
 Kingston, ON Child Development Centre, Hotel Dieu 
Hospital
Queen’s University Dr. Garth Smith
 Montreal, QC Montreal Children’s Hospital McGill University Dr. Maryam Oskoui
 Fredericton, NB Stan Cassidy Rehabilitation Centre University of New Brunwick/
Dalhousie University
Dr. Colleen O’Connell 
and 
Dr. Scott Worley 
 Halifax, NS IWK Health Centre Dalhousie University Dr. Joseph Dooley
 Winnipeg, MB Winnipeg Health Sciences Centre University of Manitoba Dr. Edward Leung
Past
 Mississauga, ON Erin Oak Kids Centre for Treatment  
and Development
None Dr. Gillian Hogan
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patients, 37 registries that enroll SMA patients, 14 registries that 
enroll DM patients and 1 of 4 registries that enroll LGMD patients 
worldwide (11). The CNDR is unique among many NM registries 
in that it is a multi-disease registry with participants enrolled and con-
sented directly in NM clinics with clinic verified data. The strengths 
of the design and organization of the CNDR have led to a number of 
successes for the paediatric NM community in Canada.
Success in clinical trial facilitation
Canada is currently without a defined orphan disease strategy, 
or even an orphan disease designation within the Health Canada 
pharmaceutical review process, which limits the incentive for 
drug development in rare diseases (12). Despite this disadvan-
tage of working in Canada, the launch of the CNDR has nonethe-
less encouraged more industry partners to consider establishing 
clinical trial sites in Canada. In our view, the development of the 
CNDR has therefore allowed Canada to be viewed more favour-
ably by biopharmaceutical companies involved in drug devel-
opment leading to clinical trial opportunities for Canadian NM 
patients. The CNDR is now exploring models for post-marketing 
surveillance for new therapies to further enhance the attractive-
ness of Canada as a market for novel therapeutics.
Registry information can also benefit research at the pre-clinical 
stage prior to human study. For example, a theoretical bioinfor-
matics study using the DMD registry in France has allowed for the 
prediction that development of a multi-exon skipping antisense oli-
gonucleotide could help 63% of patients with dystrophin deletions, 
in contrast to single exon skipping of even the most frequently 
deleted exons which would help only 16% of affected boys (13).
Although randomized clinical trials (RCTs) are the gold stan-
dard for providing clinical evidence to guide treatment decisions, 
the costs of RCTs in the rare disease population are prohibitive and 
participants are not always representative of the patient population 
at large. One proposed solution is registry-based RCTs (14,15). 
This type of trial design has been used an open-label method to 
evaluate treatments, strategies and devices. The baseline and end 
points are already included in the database. Registry-based clinical 
trials are relatively simple to design, far less costly and more appli-
cable to real-world patients compared with RCTs. The CNDR is 
an ideal registry for identifying patients eligible for enrollment in 
registry-based randomized trials.
Success in facilitating other clinical research
Although the planning, facilitation and implementation of 
clinical trials are paramount objectives for the CNDR, it 
also enables many other important research initiatives. The 
Table 2. Diagnostic and genetic characteristics of paediatric patients with dystrophinopathies, SMA and DM
Diagnosis (N) Breakdown by disease subtype Genetic information
Dystrophinopathies 
(245)
Duchenne Becker Intermediate Mutation types
224 18 3 Deletions Duplications Point mutations Negative Unknown
162 25 28 5 29
SMA (98) Type 1 Type II Type III Distal SMA Unknown* SMN2 copy numbers
28 46 19 3 2 Type I (N = 23) Type II (N = 27) Type III (N = 7)
2.3 3.0 3.7
DM (58) Congenital DM DM type I  Average number of CTG repeats
30 22 Congenital (N = 24) DM1 (N = 18)
1469 650
DM Myotonic dystrophy; SMA Spinal muscular atrophy; SMN2 Survivor motor neuron 2. *SMA was originally a pending disease and disease 
subtype information was not collected
Dystrophinopathies
40%
Limb Girdle 
Muscular
Dystrophies
10%
Spinal Muscular 
Atrophy
16%
Myotonic Dystrophy
9%
Charcot-Marie-
Tooth Disease
9%
Others
16%
Figure  1. Breakdown of paediatric diseases in the Canadian 
Neuromuscular Disease Registry. Dystrophinopathies include Duchenne, 
Becker and intermediate muscular dystrophies. A  detailed breakdown of 
other neuromuscular disorders can be found in Table 4
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CNDR has facilitated a variety of clinical and survey-based 
studies including the ongoing longitudinal study examining 
health-related quality of life (HRQOL) in boys with DMD. 
This is one of the largest and most representative HRQOL 
studies in this population and has already yielded intriguing 
results. Notably, subjective levels of fatigue were found to be 
highly associated with HRQOL, suggesting reducing levels of 
fatigue could lead to improvement of HRQOL in the paedi-
atric DMD population (9). The CNDR plays a crucial role 
in the ongoing success of this project, from assisting with 
patient enrollment through study notifications and providing 
accurate clinical data.
The CNDR can also foster collaborations between specialists 
in the NM field and paediatricians and paediatric health care 
professionals from other disciplines, studying a wide range 
of issues, such as those pertaining to chronic disease, genetic 
disorders, transition to adult care, end-o-life care, quality of life, 
health service delivery and health maintenance.
Multi-disease, clinic-based model optimizes efficiency 
and accuracy of data collection
The CNDR is a comprehensive registry that has the capac-
ity to enroll all patients with a NM disease. While DMD, 
DM, LGMD and SMA are the diseases of focus, there is 
value in collecting basic demographic information on 
other NM diseases. These diseases are even more rare, thus 
recruitment for clinical trial and other research studies is 
even more challenging. A centrally managed database that 
harmonizes participant information collection is the most 
efficient way of achieving this goal, ensuring that partici-
pants with even the rarest NM diseases are not overlooked 
for research.
Table 3. Clinical characteristics of paediatric patients with dystrophinopathies, spinal muscular atrophy and myotonic dystrophy
Diagnosis (N) Average 
age (years)
Clinical trial 
participation
Ambulation (N) Non-invasive  
ventilation (N)
Invasive  
ventilation (N)
Yes (no, 
unknown)
Yes No Unknown Yes No Unknown Yes No Unknown
Dystrophinopathies (249) 12 60 (148, 41) 178 45 25 6 216 25 0 224 25
Spinal muscular 
atrophy (85)*
9 3 (49, 33) 7 34 6 24 46 15 2 68 15
Myotonic dystrophy (58) 10 No data 39 12 7 6 43 9 3 46 9
*Only includes spinal muscular atrophy patients for whom medical information is available (i.e., indexed patients)
Table 4. Non-index diseases included in the CNDR
Muscle (N=40) Nerve (N=18) Neuromuscular junction (N=13) Other (N=11) 
Congenital muscular  
dystrophy (20)
Friedreich’s ataxia (8) Myasthenia gravis (7) Arthrogryposis (5)
Myasthenia gravis—ocular (1) Amyoplasia (5) 
Congenital muscular dystrophy— 
Merosin deficiency (7)
Hereditary sensory autonomic  
neuropathy (4)
Myasthenic syndrome/congenital  
myasthenic syndrome (5)
Motor neuron 
disease (1)
Mitochondrial myopathy (2) 
Facioscapulohumeral muscular  
dystrophy (7) 
Chronic inflammatory 
demyelinating  
polyneuropathy (1)
Poland syndrome (1)
Dejerine-Sottas disease (1)
Myotonia congenita—Thomsen 
disease (2)
Hereditary neuralgia  
amyotrophy (1)
Paramyotonia congenital (4)
Dermatomyositis (1)
Hereditary neuropathy with 
liabilitiy to pressure palsies (2)
King-Denborough disease (1) Peripheral neuropathy (1)
X-linked myopathy with excessive  
autophagy (1)
CNDR Canadian Neuromuscular Disease Registry; PTEN Phosphatase and tensin homolog
Downloaded from https://academic.oup.com/pch/article-abstract/23/1/20/4706301
by University of Western Ontario user
on 30 July 2018
Paediatrics & Child Health, 2018, Vol. 23, No. 1 25
The decision to run a clinic-based enrollment and data entry 
model for the CNDR was based on several goals: retaining par-
ticipants through regular clinic contact, increasing the accuracy 
of data through data collection from clinic charts by trained 
personnel and assuring full and ongoing informed consent. The 
inadequacy of follow-up in self-report registries has been out-
lined in a paper contrasting an active surveillance registry with 
a patient-driven registry for DM; these include several clini-
cally relevant pieces of information being missing and concerns 
regarding accuracy of reported data due to recall bias (16).
Potential as a clinic-management tool and 
 epidemiologic tool
Although NM diseases are known to comprise a sizeable com-
ponent of the neurological burden of disease globally, the 
 epidemiologic data available for specific NM diseases in Canada 
or globally remain very limited. In this regard, CNDR data have 
already contributed to global collection of epidemiological data, 
ranging from mutation types and frequencies (17) to monitor-
ing of disease trends and care practices (18). However, at pres-
ent, there are gaps in patient recruitment as not all Canadian 
paediatric NM clinics are enrolling in the CNDR, and so the 
CNDR numbers should not be considered a comprehensive 
epidemiological tool. A  registry that is embedded within the 
clinic setting can have a beneficial quality assurance impact, 
ensuring that patients are not ‘falling through the cracks’ of a 
busy practice, flagging that a participant is overdue for a visit or 
has not had a certain test at the indicated time. Further, national 
practice differences can be examined using registry data as has 
been done for cystic fibrosis resulting in advanced and more 
codified standards of care (19). The CNDR aims to increase 
this potential function of the registry over time.
Funding model
The CNDR has a unique funding structure: it is funded by a 
mix of charitable and industry sponsors and entirely unfunded 
by government or research grant agencies. Each sponsor 
assumes a portion of the registry’s central operating costs and 
covers disease-specific costs for their disease of choice. In this 
way, each sponsoring organization is able to minimize individ-
ual costs while maximizing collective benefit and multiplying 
the value of every dollar invested.
CONCLUSIONS
The CNDR is a clinic-based registry of national scope that has 
been successful in connecting Canadian NM patients to national 
and international clinical trials and other research initiatives. With 
the recent launch of a national rare disease strategy, the advent of 
next-generation sequencing diagnoses, the burgeoning interest 
of pharmaceutical and biotechnology industries in rare disease 
and the resulting rare disease therapeutic pipeline, there will be 
increasing focus on, and opportunities for, rare disease clinical 
trials for NM diseases. The CNDR will act as a valuable resource 
enabling capture of national data and facilitating a network of 
geographically disparate teams to help to rectify this gap. The 
registry will continue to engage stakeholders to enable and sup-
port research into potential treatments, with specific measures of 
success being the number of studies and publications with high 
impact that are realized due to the CNDR. Paediatric clinicians 
and researchers are encouraged to submit research proposals or 
data requests that will engage the Canadian paediatric NM com-
munity and ultimately deliver benefits to NM patients.
Acknowledgements
The authors would like to thank Jane Terhaerdt and Dr. Laura McAdam 
for providing valuable feedback on the manuscript. The authors would 
also like to thank national and regional CNDR coordinators for main-
taining the registry at its highest quality. The CNDR has been supported 
by the ALS Society of Canada, Biogen, Families of SMA Canada, Jesse’s 
Journey, the Marigold Foundation and the Starratt Family Foundation. 
S.V. reports CME Honoria Speaker’s fees from Genzyme Canada. M.O. is 
part of a Ionis clinical trial, part of the Biogen SMA expert panel and has 
received funding from the Sick Kids Foundation for a study on cerebral 
palsy. L.K. reports grants from Jesse’s Journey, ALS Canada, Families of 
SMA, Marigold Foundation, Biogen Idec and Starratt Family Foundation 
during the conduct of the study. C.C.  is the Chair of the Canadian 
Advisory Board, a site investigator for clinical trials and received support 
for scientific meetings from PTC Therapeutics. C.C. also reports to be 
part of Biomarin and Ionis/Biogen clinical trials and received funding 
from Biomarin and Ionis/Biogen to travel to consultant meetings and 
Eli Lily, Acceleron and GSK to travel to investigator meetings, and grants 
from Valerion Pharmaceuticals and Jesse’s journey Foundation. The 
Canadian Neuromuscular Disease Registry is housed at the University 
of Calgary and ethics approval was obtained from the Conjoint Health 
Research Ethics Board (CHREB) at the University of Calgary.
References
1. Rowland LP, McLeod JG. Classification of neuromuscular dis-
orders. J Neurol Sci 1994;124(Suppl.):109–30.
2. Campbell C, Levin S, Siu VM, Venance S, Jacob P. Congenital 
myotonic dystrophy: Canadian population-based surveillance 
study. J Pediatr 2013;163(1):120–5, e1–3.
3. Theadom A, Rodrigues M, Roxburgh R, et  al. Prevalence 
of muscular dystrophies: A  systematic literature review. 
Neuroepidemiology 2014;43(3–4):259–68.
4. D’Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular 
atrophy. Orphanet J Rare Dis 2011;6:71.
5. Bushby K, Lynn S, Straub T, TREAT-NMD Network. 
Collaborating to bring new therapies to the patient—
the TREAT-NMD model. Acta Myol Myopathies 
Cardiomyopathies 2009;28(1):12–5.
Downloaded from https://academic.oup.com/pch/article-abstract/23/1/20/4706301
by University of Western Ontario user
on 30 July 2018
26 Paediatrics & Child Health, 2018, Vol. 23, No. 1
 6. Sárközy A, Bushby K, Béroud C, Lochmüller H. 157th ENMC 
International Workshop: Patient registries for rare,  inherited 
muscular disorders, 25–27 January 2008, Naarden, the 
Netherlands. Neuromuscul Disord 2008;18(12):997–1001.
 7. Korngut L, Campbell C, Johnston M, et  al. The CNDR: 
Collaborating to translate new therapies for Canadians. Can J 
Neurol Sci. 2013;40(5):698–704.
 8. Bladen CL, Rafferty K, Straub V, et  al. The TREAT-NMD 
Duchenne muscular dystrophy registries: Conception, 
design, and utilization by industry and academia. Hum Mutat 
2013;34(11):1449–57.
 9. Wei Y, Speechley KN, Zou G, Campbell C. Factors associated 
with health-related quality of life in children with Duchenne 
muscular dystrophy. J Child Neurol 2016;31(7):879–86.
10. Johnson NE, Ekstrom A-B, Campbell C, et  al. Parent-
reported multi-national study of the impact of congenital and 
childhood onset myotonic dystrophy. Dev Med Child Neurol 
2016;58(7):698–705.
11. TREAT-NMD: List of Registries by Disease [Internet]. <www.
treat-nmd.eu/resources/patient-registries/list/> (Accessed 
January 26, 2016).
12. Our Work | Canadian Organization for Rare Disorders 
[Internet]. <www.raredisorders.ca/our-work/> (Accessed 
January 26, 2016).
13. Béroud C, Tuffery-Giraud S, Matsuo M, et  al. Multiexon 
skipping leading to an artificial DMD protein lacking amino 
acids from exons 45 through 55 could rescue up to 63% of 
patients with Duchenne muscular dystrophy. Hum Mutat 
2007;28(2):196–202.
14. Lauer M, D’Agostino R. The randomized registry trial—the 
next disruptive technology in clinical research? N Engl J Med 
2013;369(17):1579–81.
15. Harrington RA. Appropriate use criteria for coronary  revas-
cularization and the learning health system: A good start. 
JAMA 2015;314(19):2029–31.
16. Prendergast P, Magalhaes S, Campbell C. Congenital myo-
tonic dystrophy in a national registry. Paediatr Child Health 
2010;15(8):514–8.
17. Bladen CL, Salgado D, Monges S, et al. The TREAT-NMD DMD 
Global Database: Analysis of more than 7,000 Duchenne mus-
cular dystrophy mutations. Hum Mutat 2015;36(4):395–402.
18. Bladen CL, Thompson R, Jackson JM, et  al. Mapping 
the  differences in care for 5,000 spinal muscular atrophy 
patients, a survey of 24 national registries in North America, 
Australasia and Europe. J Neurol 2014;261(1):152–63.
19. The Canadian CF Registry Data—Cystic Fibrosis Canada 
[Internet]. <www.cysticfibrosis.ca/cf-care/cf-registry/the- 
canadian-cf-registry-data/> (Accessed January 26, 2016).
Downloaded from https://academic.oup.com/pch/article-abstract/23/1/20/4706301
by University of Western Ontario user
on 30 July 2018
